advertisment

Your new biomedical search engine
try: asthma , trastuzumab , BRCA1 , Collins, F 		Advanced Search
Preferences
Search in:
Show highlight panel
Sign Up for mynovoseek and enjoy more functionalities in novoseek sign up for free now!
About novoseek

Free biomedical search engine that allows you to find literature in Pubmed, Free Full Text and U.S. Grants. Explore the results in an easy way, narrow and identify relevant results quickly.

Check tutorial video
Read a use case

Key concepts


Click here for more info about 'cardiac siderosis'
cardiac siderosis
ranking
Click here for more info about 'deferasirox'
deferasirox
ranking
Click here for more info about 'iron chelation'
iron chelation
ranking
Click here for more info about 'chelation therapies'
chelation therapies
ranking
Click here for more info about 'iron overload'
iron overload
ranking
more
Print

Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.

Ann Hematol 2010,Apr,01;89(4):405-9; (PMID: 19798501)
Publication Type: Clinical Trial, Phase IV, Multicenter Study, Research Support, Non-U.S. Gov't, Journal Article
Annals of hematology
Sultan Qaboos University Hospital, Muscat, Oman.
article abstract
Noninvasive measurement of tissue iron levels can be assessed using T2* magnetic resonance imaging (MRI) to identify and monitor patients with iron overload. This study monitored cardiac siderosis using T2* MRI in a cohort of 19 heavily iron-overloaded patients with beta-thalassemia major receiving iron chelation therapy with deferasirox over an 18-month period. Overall, deferasirox therapy significantly improved mean + or - standard deviation cardiac T2* from a baseline of 17.2 + or - 10.8 to 21.5 + or - 12.8 ms (+25.0%; P = 0.02). A concomitant reduction in median serum ferritin from a baseline of 5,497 to 4,235 ng/mL (-23.0%; P = 0.001), and mean liver iron concentration from 24.2 + or - 9.0 to 17.6 + or - 12.9 mg Fe/g dry weight (-27.1%; P = 0.01) was also seen. Improvements were seen in patients with various degrees of cardiac siderosis, including those patients with a baseline cardiac T2* of <10 ms, indicative of high cardiac iron burden. These findings therefore support previous observations that deferasirox is effective in the removal of myocardial iron with concomitant reduction in total body iron.
Mesh Terms
Adolescent
Benzoic Acids
Female
Heart Diseases
Iron
more
Your search has been saved.
Your search contains date ranges. It can be saved but no alerts can be created. To create an alert please repeat the search without date ranges.
myns_savedsearch.alertcreated
close
Your search has been saved.
Do you want to create an email alert?
close

Labels will enable you to:

  • Organize your favorite papers.
  • Classify interesting documents.
  • Retrieve your labeled documents from anywhere at anytime.

To assign your labels to the documents we need you to sign-in or create an account.

close

Saving search results will enable you to:

  • Retrieve saved results from anywhere at anytime.
  • Set up emails alerts on your favorite searches.

To keep all this information stored we need you to sign-in or create an account.

close

novoseek allows you to:

  • Claim authorship of your work.
  • Specify the different aliases you have in your work.
  • Build your profile and your author page!

To keep all this information stored we need you to sign-in or create an account.

The entity has already been added to the filters
This article will be available in PMC on .
Create Label close
Name of label: